登革热疫苗：进展和挑战。

IF 13.1 1区医学 Q1 PHARMACOLOGY & PHARMACY

Annual review of pharmacology and toxicology Pub Date : 2025-08-18 DOI:10.1146/annurev-pharmtox-062124-040711

Alan L Rothman, Heather Friberg

{"title":"登革热疫苗：进展和挑战。","authors":"Alan L Rothman, Heather Friberg","doi":"10.1146/annurev-pharmtox-062124-040711","DOIUrl":null,"url":null,"abstract":"Development of vaccines against dengue has been designated a priority for over 75 years. The completion of Phase III trials and licensing of multiple dengue vaccines have been significant accomplishments of the last 15 years. Despite that progress, a vaccine suitable for broad use has not yet been identified. The scientific challenges of multiple dengue viral serotypes, immune imprinting from previous infections, and immune enhancement of infection and disease remain formidable obstacles to this goal. Further investments in clinical research of natural dengue virus infections and participants in dengue vaccine trials will be needed to enable the development and testing of the next generation of dengue vaccines.","PeriodicalId":8057,"journal":{"name":"Annual review of pharmacology and toxicology","volume":" ","pages":""},"PeriodicalIF":13.1000,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Dengue Fever Vaccines: Progress and Challenges.\",\"authors\":\"Alan L Rothman, Heather Friberg\",\"doi\":\"10.1146/annurev-pharmtox-062124-040711\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Development of vaccines against dengue has been designated a priority for over 75 years. The completion of Phase III trials and licensing of multiple dengue vaccines have been significant accomplishments of the last 15 years. Despite that progress, a vaccine suitable for broad use has not yet been identified. The scientific challenges of multiple dengue viral serotypes, immune imprinting from previous infections, and immune enhancement of infection and disease remain formidable obstacles to this goal. Further investments in clinical research of natural dengue virus infections and participants in dengue vaccine trials will be needed to enable the development and testing of the next generation of dengue vaccines.\",\"PeriodicalId\":8057,\"journal\":{\"name\":\"Annual review of pharmacology and toxicology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":13.1000,\"publicationDate\":\"2025-08-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annual review of pharmacology and toxicology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1146/annurev-pharmtox-062124-040711\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annual review of pharmacology and toxicology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1146/annurev-pharmtox-062124-040711","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

摘要

75年来，研制登革热疫苗一直被列为优先事项。完成三期试验和许可多种登革热疫苗是过去15年取得的重大成就。尽管取得了这些进展，但尚未确定适合广泛使用的疫苗。多种登革热病毒血清型、以前感染的免疫印记以及感染和疾病的免疫增强等科学挑战仍然是实现这一目标的巨大障碍。将需要对天然登革热病毒感染的临床研究和登革热疫苗试验的参与者进行进一步投资，以便能够开发和测试下一代登革热疫苗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Dengue Fever Vaccines: Progress and Challenges.

Development of vaccines against dengue has been designated a priority for over 75 years. The completion of Phase III trials and licensing of multiple dengue vaccines have been significant accomplishments of the last 15 years. Despite that progress, a vaccine suitable for broad use has not yet been identified. The scientific challenges of multiple dengue viral serotypes, immune imprinting from previous infections, and immune enhancement of infection and disease remain formidable obstacles to this goal. Further investments in clinical research of natural dengue virus infections and participants in dengue vaccine trials will be needed to enable the development and testing of the next generation of dengue vaccines.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Annual review of pharmacology and toxicology 医学-毒理学

CiteScore

27.80

自引率

0.00%

发文量

期刊介绍： Since 1961, the Annual Review of Pharmacology and Toxicology has been a comprehensive resource covering significant developments in pharmacology and toxicology. The journal encompasses various aspects, including receptors, transporters, enzymes, chemical agents, drug development science, and systems like the immune, nervous, gastrointestinal, cardiovascular, endocrine, and pulmonary systems. Special topics are also featured in this annual review.